Patents by Inventor Naijing Su

Naijing Su has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CRYSTALLINE FORMS OF A KRAS INHIBITOR
    Publication number: 20250115603
    Abstract: This disclosure provides salts, crystalline forms, and formulations of a KRAS inhibitor, and methods of making and using thereof.
    Type: Application
    Filed: October 8, 2024
    Publication date: April 10, 2025
    Inventors: Jiemin Hu, Zhongjiang Jia, Trupti Sheth, Naijing Su, Huaping Zhang
  • PROCESS OF PREPARING A PD-1/PD-L1 INHIBITOR
    Publication number: 20240376106
    Abstract: The present invention relates to processes of preparing PD-1/PD-L1 inhibitor (R)-1-((7-cyano-2-(3?-(3-(((R)-3-hydroxypyrrolidin-1-yl)methyl)-1,7-naphthyridin-8-ylamino)-2,2?-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)pyrrolidine-3-carboxylic acid, or salts thereof, related synthetic intermediates, and salts of the intermediates, where the PD-1/PD-L1 inhibitor is useful in the treatment of various diseases including infectious diseases and cancer.
    Type: Application
    Filed: July 24, 2024
    Publication date: November 14, 2024
    Inventors: Jiacheng Zhou, Shili Chen, Zhongjiang Jia, Yi Li, Qiyan Lin, Pingli Liu, Yongchun Pan, Timothy Martin, Bo Shen, Chongsheng Eric Shi, Naijing Su, Yongzhong Wu, Michael Xia
  • PROCESS AND INTERMEDIATES FOR PREPARING A JAK INHIBITOR
    Publication number: 20240368171
    Abstract: The present disclosure is related to processes for preparing baricitinib, salts thereof, and related synthetic intermediate compounds and salts thereof.
    Type: Application
    Filed: July 16, 2024
    Publication date: November 7, 2024
    Inventors: Jiacheng Zhou, Shili Chen, Zhongjiang Jia, Pingli Liu, David Meloni, Yongchun Pan, Naijing Su, Michael Xia
  • Process of preparing a PD-1/PD-L1 inhibitor
    Patent number: 12084443
    Abstract: The present invention relates to processes of preparing PD-1/PD-L1 inhibitor (R)-1-((7-cyano-2-(3?-(3-(((R)-3-hydroxypyrrolidin-1-yl)methyl)-1,7-naphthyridin-8-ylamino)-2,2?-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)pyrrolidine-3-carboxylic acid, or salts thereof, related synthetic intermediates, and salts of the intermediates, where the PD-1/PD-L1 inhibitor is useful in the treatment of various diseases including infectious diseases and cancer.
    Type: Grant
    Filed: August 31, 2023
    Date of Patent: September 10, 2024
    Assignee: Incyte Corporation
    Inventors: Jiacheng Zhou, Zhongjiang Jia, Qiyan Lin, Pingli Liu, Yongchun Pan, Timothy Martin, Bo Shen, Naijing Su, Yongzhong Wu
  • Process and intermediates for preparing a JAK inhibitor
    Patent number: 12071439
    Abstract: The present disclosure is related to processes for preparing baricitinib, salts thereof, and related synthetic intermediate compounds and salts thereof.
    Type: Grant
    Filed: July 11, 2022
    Date of Patent: August 27, 2024
    Assignee: Incyte Corporation
    Inventors: Jiacheng Zhou, Shili Chen, Zhongjiang Jia, Pingli Liu, David Meloni, Yongchun Pan, Naijing Su, Michael Xia
  • PROCESS AND INTERMEDIATES FOR PREPARING A JAK1 INHIBITOR
    Publication number: 20240246982
    Abstract: The present invention is related to processes for preparing itacitinib, or a salt thereof, and related synthetic intermediates related thereto.
    Type: Application
    Filed: December 19, 2023
    Publication date: July 25, 2024
    Inventors: Jiacheng Zhou, Shili Chen, Pingli Liu, David J. Meloni, Yongchun Pan, Naijing Su, Michael Xia
  • Nicotinamide phosphoribosyltransferase inhibitors and methods for use of the same
    Patent number: 12030901
    Abstract: Disclosed herein are compounds that can act as inhibitors of nicotinamide phosphoribosyltransferase (“NAMPT”), and methods for their use in treating or preventing diseases, such as pulmonary arterial hypertension (“PAH”). The compounds described herein can include compounds of Formula (II) and pharmaceutically acceptable salts thereof: wherein the substituents are as described.
    Type: Grant
    Filed: November 16, 2022
    Date of Patent: July 9, 2024
    Assignees: THE TRUSTEES OF INDIANA UNIVERSITY, The Board of Trustees of the University of Illinois
    Inventors: Tom G. Driver, Roberto F. Machado, Naijing Su, Xinyu Guan, Wrickban Mazumdar, Kira Ratia, Jason Ralph Hickok, Angelia Denise Lockett
  • PROCESS AND INTERMEDIATES FOR PREPARING A JAK INHIBITOR
    Publication number: 20240166655
    Abstract: The present invention is related to processes for preparing ruxolitinib, or a salt thereof, and related synthetic intermediates related thereto.
    Type: Application
    Filed: December 15, 2023
    Publication date: May 23, 2024
    Inventors: Jiacheng Zhou, Shili Chen, Pingli Liu, David J. Meloni, James M. Parks, Yongchun Pan, Naijing Su, Michael Xia, Weiguo Liu
  • SALTS AND CRYSTALLINE FORMS OF A PD-1/PD-L1 INHIBITOR
    Publication number: 20240132523
    Abstract: This application relates to solid forms and salt forms of the PD-1/PD-L1 inhibitor 4,4?-(((((2,2?-dichloro-[1,1?-biphenyl]-3,3?-diyl)bis(azanediyl))bis(carbonyl))bis(1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-2,5-diyl))bis(ethane-2,1-diyl))bis(bicyclo[2.2.1]heptane-1-carboxylic acid), including processes of preparation thereof, where the solid forms and salt forms are useful in the treatment of various diseases including infectious diseases and cancer.
    Type: Application
    Filed: November 21, 2023
    Publication date: April 25, 2024
    Inventors: Zhongjiang Jia, Shili Chen, Yi Li, Timothy Martin, Bo Shen, Naijing Su, Jiacheng Zhou, Qun Li
  • Process and intermediates for preparing a JAK inhibitor
    Patent number: 11905292
    Abstract: The present invention is related to processes for preparing ruxolitinib, or a salt thereof, and related synthetic intermediates related thereto.
    Type: Grant
    Filed: August 17, 2021
    Date of Patent: February 20, 2024
    Assignee: Incyte Corporation
    Inventors: Jiacheng Zhou, Shili Chen, Pingli Liu, David J. Meloni, James M. Parks, Yongchun Pan, Naijing Su, Michael Xia, Weiguo Liu
  • Process and intermediates for preparing a JAK1 inhibitor
    Patent number: 11897889
    Abstract: The present invention is related to processes for preparing itacitinib, or a salt thereof, and related synthetic intermediates related thereto.
    Type: Grant
    Filed: August 17, 2021
    Date of Patent: February 13, 2024
    Assignee: Incyte Corporation
    Inventors: Jiacheng Zhou, Shili Chen, Pingli Liu, David J. Meloni, Yongchun Pan, Naijing Su, Michael Xia
  • Salts and crystalline forms of a PD-1/PD-L1 inhibitor
    Patent number: 11866451
    Abstract: This application relates to solid forms and salt forms of the PD-1/PD-L1 inhibitor 4,4?-(((((2,2?-dichloro-[1,1?-biphenyl]-3,3?-diyl)bis(azanediyl))bis(carbonyl))bis(1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-2,5-diyl))bis(ethane-2,1-diyl))bis(bicyclo[2.2.1]heptane-1-carboxylic acid), including processes of preparation thereof, where the solid forms and salt forms are useful in the treatment of various diseases including infectious diseases and cancer.
    Type: Grant
    Filed: November 10, 2020
    Date of Patent: January 9, 2024
    Assignee: Incyte Corporation
    Inventors: Zhongjiang Jia, Shili Chen, Yi Li, Timothy Martin, Bo Shen, Naijing Su, Jiacheng Zhou, Qun Li
  • PROCESS OF PREPARING A PD-1/PD-L1 INHIBITOR
    Publication number: 20230406852
    Abstract: The present invention relates to processes of preparing PD-1/PD-L1 inhibitor (R)-1-((7-cyano-2-(3?-(3-(((R)-3-hydroxypyrrolidin-1-yl)methyl)-1,7-naphthyridin-8-ylamino)-2,2?-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)pyrrolidine-3-carboxylic acid, or salts thereof, related synthetic intermediates, and salts of the intermediates, where the PD-1/PD-L1 inhibitor is useful in the treatment of various diseases including infectious diseases and cancer.
    Type: Application
    Filed: August 31, 2023
    Publication date: December 21, 2023
    Inventors: Jiacheng Zhou, Shili Chen, Zhongjiang Jia, Yi Li, Qiyan Lin, Pingli Liu, Yongchun Pan, Timothy Martin, Bo Shen, Chongsheng Eric Shi, Naijing Su, Yongzhong Wu, Michael Xia
  • Process of preparing a PD-1/PD-L1 inhibitor
    Patent number: 11780836
    Abstract: The present invention relates to processes of preparing PD-1/PD-L1 inhibitor (R)-1-((7-cyano-2-(3?-(3-(((R)-3-hydroxypyrrolidin-1-yl)methyl)-1,7-naphthyridin-8-ylamino)-2,2?-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)pyrrolidine-3-carboxylic acid, or salts thereof, related synthetic intermediates, and salts of the intermediates, where the PD-1/PD-L1 inhibitor is useful in the treatment of various diseases including infectious diseases and cancer.
    Type: Grant
    Filed: November 5, 2021
    Date of Patent: October 10, 2023
    Assignee: Incyte Corporation
    Inventors: Jiacheng Zhou, Shili Chen, Zhongjiang Jia, Yi Li, Qiyan Lin, Pingli Liu, Yongchun Pan, Timothy Martin, Bo Shen, Chongsheng Eric Shi, Naijing Su, Yongzhong Wu, Michael Xia
  • SALTS AND SOLID FORMS OF AN FGFR INHIBITOR AND PROCESSES OF PREPARING THEREOF
    Publication number: 20230192722
    Abstract: The present invention relates to salts and solid forms of the FGFR inhibitor (7R,8aS)-2-(5-(5-(2,3-Dimethylphenyl)-6-methoxy-1H-pyrazolo[4,3-b]pyridin-3-yl)pyridin-2-yl)octahydropyrrolo[1,2-a]pyrazin-7-ol, including methods of preparation thereof, wherein the compounds, salts, and solid forms are useful in the treatment of FGFR-mediated diseases such as cancer.
    Type: Application
    Filed: December 21, 2022
    Publication date: June 22, 2023
    Inventors: Pingli Liu, Zhongjiang Jia, Qiyan Lin, Naijing Su, Timothy Martin, Michael Xia, Jiacheng Zhou, Baoyu Mi
  • PROCESS AND INTERMEDIATES FOR PREPARING A JAK INHIBITOR
    Publication number: 20230059389
    Abstract: The present disclosure is related to processes for preparing baricitinib, salts thereof, and related synthetic intermediate compounds and salts thereof.
    Type: Application
    Filed: July 11, 2022
    Publication date: February 23, 2023
    Inventors: Jiacheng Zhou, Shili Chen, Zhongjiang Jia, Pingli Liu, David Meloni, Yongchun Pan, Naijing Su, Michael Xia
  • PROCESS OF PREPARING A PD-1/PD-L1 INHIBITOR
    Publication number: 20220144830
    Abstract: The present invention relates to processes of preparing PD-1/PD-L1 inhibitor (R)-1-((7-cyano-2-(3?-(3-(((R)-3-hydroxypyrrolidin-1-yl)methyl)-1,7-naphthyridin-8-ylamino)-2,2?-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)pyrrolidine-3-carboxylic acid, or salts thereof, related synthetic intermediates, and salts of the intermediates, where the PD-1/PD-L1 inhibitor is useful in the treatment of various diseases including infectious diseases and cancer.
    Type: Application
    Filed: November 5, 2021
    Publication date: May 12, 2022
    Inventors: Jiacheng Zhou, Shili Chen, Zhongjiang Jia, Yi Li, Qiyan Lin, Pingli Liu, Yongchun Pan, Timothy Martin, Bo Shen, Chongsheng Eric Shi, Naijing Su, Yongzhong Wu, Michael Xia
  • PROCESS AND INTERMEDIATES FOR PREPARING A JAK INHIBITOR
    Publication number: 20220056035
    Abstract: The present invention is related to processes for preparing ruxolitinib, or a salt thereof, and related synthetic intermediates related thereto.
    Type: Application
    Filed: August 17, 2021
    Publication date: February 24, 2022
    Inventors: Jiacheng Zhou, Shili Chen, Pingli Liu, David J. Meloni, James M. Parks, Yongchun Pan, Naijing Su, Michael Xia
  • PROCESS AND INTERMEDIATES FOR PREPARING A JAK1 INHIBITOR
    Publication number: 20220056034
    Abstract: The present invention is related to processes for preparing itacitinib, or a salt thereof, and related synthetic intermediates related thereto.
    Type: Application
    Filed: August 17, 2021
    Publication date: February 24, 2022
    Inventors: Jiacheng Zhou, Shili Chen, Pingli Liu, David J. Meloni, Yongchun Pan, Naijing Su, Michael Xia
  • SALTS AND CRYSTALLINE FORMS OF A PD-1/PD-L1 INHIBITOR
    Publication number: 20210139511
    Abstract: This application relates to solid forms and salt forms of the PD-1/PD-L1 inhibitor 4,4?-(((((2,2?-dichloro-[1,1?-biphenyl]-3,3?-diyl)bis(azanediyl))bis(carbonyl))bis(1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-2,5-diyl))bis(ethane-2,1-diyl))bis(bicyclo[2.2.1]heptane-1-carboxylic acid), including processes of preparation thereof, where the solid forms and salt forms are useful in the treatment of various diseases including infectious diseases and cancer.
    Type: Application
    Filed: November 10, 2020
    Publication date: May 13, 2021
    Inventors: Zhongjiang Jia, Shili Chen, Yi Li, Timothy Martin, Bo Shen, Naijing Su, Jiacheng Zhou, Qun Li